Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

s release related July 16, 2009 for more information about the Phase I clinical trial.
  • In a double-blind test, for the purpose of conducting the clinical trial in a completely objective manner, the physicians performing the trial as well as the patients participating in the trial do not know if the substance administered to each individual is the drug being tested or the placebo.
  • The placebo is a substance that does not include the drug being tested (RK-023 in this case).
  • About R-Tech Ueno, Ltd.

    R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation," targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent. The company's main product Rescula(R) eyedrop 0.12% is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance "prostone" in the development of Rescula(R). Prostone was discovered in 1980 by Dr. Ryuji Ueno, the founder of the company. Rescula(R) eyedrop 0.12% that causes less topical and systemic adverse reactions demonstrates steady ocular pressure-decreasing action by twice-a-day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow-increasing mechanism.

        Stock Code: No.4573, Osaka Securities Exchange; Hercules
        Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
        Representative Director & President: Yukihiko Mashima
    
    
        Contact:
        Koji Nakamura,
        Business Management Department
        R-Tech Ueno, Ltd.
        Tel: +81-3-3596-8011
        e-mail: koji.nakamura@rtueno.co.jp
        URL: '/>"/>
    SOURCE R-Tech Ueno, Ltd.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
    2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
    3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
    4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
    5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
    6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
    7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
    8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
    9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
    10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
    11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/1/2014)...   Royal Philips (NYSE: ... and eCareCompanion telehealth applications have received 510(k) clearance ... A part of Philips Hospital to Home,s ... are focused on patient care within the home ... available through the cloud-based digital health platform, which ...
    (Date:10/1/2014)... LAUSANNE , Suisse, October 1, 2014 /PRNewswire/ ... génomique clinique et dans le domaine de l,analyse ... a lancé aujourd,hui une solution de diagnostic in ... d,exécuter une analyse complète de la mucoviscidose dans ... d,identifier et de caractériser tous les types de ...
    (Date:9/30/2014)... 30, 2014  Wrightington, Wigan ... MDRX ) are delighted to announce WWL,s ... new health information system. The system will be implemented ... the way WWL delivers healthcare in the future. ... record of on-time and on-budget system implementations as well ...
    Breaking Medicine Technology:Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4
    ... , July 28 HemaQuest Pharmaceuticals, a ... sickle cell disease, beta thalassemia and EBV-related cancers, announced ... to its Series B financing by new investor, Latterell ... financing to $16M . The financing is intended ...
    ... July 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. ... Proxy Advisory Services,("ISS"), a leading independent proxy voting and corporate ... River,s proposed,acquisition of WuXi. Two other proxy advisory services, Glass ... the,transaction. , , ...
    Cached Medicine Technology:HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 2ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 3ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 4ISS Recommends That WuXi Shareholders Vote for Proposed Combination With Charles River 5
    (Date:10/1/2014)... October 01, 2014 Lifeinsurance-policy.com has ... the best life insurance prices for smokers. , Smoking ... insurance premiums. Comparing quotes is the best method to ... quotes for customers who need coverage. , Whole ... duration of the policy. Since the coverage is permanent, ...
    (Date:10/1/2014)... 2014 Phoseon Technology, the pioneer in ... expand the business worldwide. This rapid growth includes increased ... for manufacturing efforts. The company has experienced average annual ... and expects this growth to continue in the future ... worldwide adoption. , “We are very pleased that ...
    (Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
    (Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
    (Date:10/1/2014)... 2014 Between 23 million and 50 ... according to figures from the National Institutes of Health ... and many of them have something else in common: ... celiac disease. Gluten Free Therapeutics, makers of CeliVites ... celiac disease by publishing a series of blog posts ...
    Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
    ... 27 New Jersey Senate Majority Leader Stephen M. Sweeney ... join Labor Leaders Charles Wowkanech , President of the New ... Counties Central Labor Council and Henry Nichola s, President of ... rallies in Deptford and Hammonton, N. J., in support of ...
    ... Governor Edward G. Rendell today announced that ... Senate confirmation:State Board of Medicine , James W. ... of Nursing Home Administrators , Mary Ann Hewston, ... creating a first-rate public education system, protecting our ...
    ... Healthier, More Productive PracticeNEWBERG, Ore., Feb. 27 ... is well-positioned to fit small spaces and conservative ... a mid-level platform choice that,s lower in cost ... performance, service, and support that distinguish A-dec products. ...
    ... can be used on all women with diagnosis, study ... new genetic test that analyzes a set of 50 ... lead to quicker, more immediate treatment for patients, according ... "Unlike a widely used genomic test that applies only ...
    ... Refute USA Today ReportHARRISBURG, Pa., Feb. 27 The ... unsafe levels of air pollutants or metals after extensively ... schools.Environmental Protection acting Secretary John Hanger said that the ... USA Today in December 2008 that relied only ...
    ... Feb. 27 Smith & Nephew, Inc.,(NYSE: ... announced the,introduction of a metal liner option for its ... in hip replacement and resurfacing,procedures. , ... Food and Drug Administration,for use with the BIRMINGHAM HIP(TM) ...
    Cached Medicine News:Health News:Politicians and Labor Leaders Set to Lead Rallies Saturday (February 28) for Striking Innova Nurses 2Health News:New A-dec 300(TM) Offers Dentists an Innovative Equipment Solution 2Health News:New Test May Mean Faster Breast Cancer Treatment 2Health News:PA DEP Finds Air Quality Around Schools to be Safe 2Health News:PA DEP Finds Air Quality Around Schools to be Safe 3Health News:Smith & Nephew Introduces Metal Liner Option for the Modular R3(TM) Acetabular Cup System 2Health News:Smith & Nephew Introduces Metal Liner Option for the Modular R3(TM) Acetabular Cup System 3
    Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
    For use with catalog #0540....
    Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
    Lupus Anticoagulant-Sensitive APTT Reagent.Cephalin with particulate activator (silica), freeze-dried....
    Medicine Products: